Effects of HRT on the risks of breast cancer and cardiovascular disease: The validity of the epidemiological evidence;Effets du THS sur le risque de cancer du sein et de maladie cardiovasculaire: La validité des preuves épidémiologiques

Gynecologie Obstetrique et Fertilite

Volumn 32, Issue 5, 2004, Pages 382-390

  Shapiro, S ^a  

^a Mailman School of Public Health   (United States)

Author keywords

Biais de d tection; Breast Cancer; Cancer du sein; Cardiovascular disease; Detection bias; Epidemiologie; pid miologie; HRT; Maladie cardiovasculaire; THS

Indexed keywords

HORMONE;

ANALYTIC METHOD; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DATA ANALYSIS; EPIDEMIOLOGICAL DATA; HORMONE SUBSTITUTION; HUMAN; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VALIDATION PROCESS;

EID: 2942662085     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2004.03.012     Document Type: Article

References (14)

1. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350:1997;1047-1059
3. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet. 362:2003;419-427
4. Shapiro S. Risks of estrogen plus progestin therapy. A sensitivity analysis of findings in the Women's Health Initiative Randomized Controlled Trial. Climacteric. 2004;. (In Press)
5. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol. 151:2000;939-2000
6. Shapiro S. Is meta-analysis a valid approach to the evaluation off small effects in observational studies? J Clin Epidemiol. 50:1997;223-229
7. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 349:2003;523-524
8. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA. 289:2003;3243-3253
9. Shapiro S. Looking to the 21st century. Have we learned from our mistakes, or are we doomed to compound them. Pharmacoepidemiology. 2002;. In press
10. Calvin F.U., Mello-Thoms C., Kandel H.L., Weinstein S.P. Course and perception of decision making during mammographic interpretation. Am J Roengenol. 179:2002;917-923
11. Greendale G.A., Reboussin B.A., Sie A., et al. Effects of estrogen-progestin on mammographic parenchymal density. Ann Intern Med. 130:1999;262-269
12. Banks E., Beral V., Cameron R., et al. Comparison of various characteristics of women who do and do not attend for breast cancer screening. Breast Cancer Research. 2001;
13. Morrison A.S., Brisson J., Khalid N. Breast cancer incidence and mortality in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst. 80:1988;1540-1547
14. Garton M., Bliss J.M., Gray, Bundred N.J., Morris J., Helmond F.A., Van Leeuwen F.E., Rookus M., Nyirjesy I. Breast cancer and hormone replacement therapy: the Million Women Study. Lancet. 2003;1328-1330. (correspondence)